JP2004149447A - Nicotine-containing ointment - Google Patents
Nicotine-containing ointment Download PDFInfo
- Publication number
- JP2004149447A JP2004149447A JP2002315622A JP2002315622A JP2004149447A JP 2004149447 A JP2004149447 A JP 2004149447A JP 2002315622 A JP2002315622 A JP 2002315622A JP 2002315622 A JP2002315622 A JP 2002315622A JP 2004149447 A JP2004149447 A JP 2004149447A
- Authority
- JP
- Japan
- Prior art keywords
- nicotine
- ointment
- weight
- smoking
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 84
- 229960002715 nicotine Drugs 0.000 title claims abstract description 69
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 239000002674 ointment Substances 0.000 title claims abstract description 57
- 239000003883 ointment base Substances 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000002562 thickening agent Substances 0.000 claims abstract description 10
- 239000000080 wetting agent Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 230000000391 smoking effect Effects 0.000 abstract description 24
- 239000000463 material Substances 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- -1 aromatic carboxylic acids Chemical class 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 230000005586 smoking cessation Effects 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 235000019788 craving Nutrition 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000779 smoke Substances 0.000 description 5
- 206010057852 Nicotine dependence Diseases 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 238000004898 kneading Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000025569 Tobacco Use disease Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 229940081733 cetearyl alcohol Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001296 polysiloxane Chemical class 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 description 1
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- 229920000536 2-Acrylamido-2-methylpropane sulfonic acid Polymers 0.000 description 1
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- AIBWPBUAKCMKNS-PPHPATTJSA-N 2-hydroxybenzoic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)C1=CC=CC=C1O.CN1CCC[C@H]1C1=CC=CN=C1 AIBWPBUAKCMKNS-PPHPATTJSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ORMHZBNNECIKOH-UHFFFAOYSA-N 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde Chemical compound CC(C)(O)CCCC1=CCC(C=O)CC1 ORMHZBNNECIKOH-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001552669 Adonis annua Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000183666 Nepsera aquatica Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 239000004113 Sepiolite Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010068887 Tobacco poisoning Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 241001593968 Vitis palmata Species 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940089116 arnica extract Drugs 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- WPKYZIPODULRBM-UHFFFAOYSA-N azane;prop-2-enoic acid Chemical compound N.OC(=O)C=C WPKYZIPODULRBM-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- NJLLQSBAHIKGKF-UHFFFAOYSA-N dipotassium dioxido(oxo)titanium Chemical compound [K+].[K+].[O-][Ti]([O-])=O NJLLQSBAHIKGKF-UHFFFAOYSA-N 0.000 description 1
- 229940106055 dodecyl benzoate Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940052296 esters of benzoic acid for local anesthesia Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- OBFVUHBJCUHVPI-UHFFFAOYSA-N pentadecyl benzoate Chemical compound CCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1 OBFVUHBJCUHVPI-UHFFFAOYSA-N 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920001921 poly-methyl-phenyl-siloxane Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000001651 pyrus cydonia seed extract Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000019355 sepiolite Nutrition 0.000 description 1
- 229910052624 sepiolite Inorganic materials 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940116411 terpineol Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- YQOBYINWABKLFC-UHFFFAOYSA-N tetradecyl benzoate Chemical compound CCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1 YQOBYINWABKLFC-UHFFFAOYSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XMLSXPIVAXONDL-UHFFFAOYSA-N trans-jasmone Natural products CCC=CCC1=C(C)CCC1=O XMLSXPIVAXONDL-UHFFFAOYSA-N 0.000 description 1
- PHXPEXIJLNFIBR-UHFFFAOYSA-N tridecyl benzoate Chemical compound CCCCCCCCCCCCCOC(=O)C1=CC=CC=C1 PHXPEXIJLNFIBR-UHFFFAOYSA-N 0.000 description 1
- USFMMZYROHDWPJ-UHFFFAOYSA-N trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium Chemical compound CC(=C)C(=O)OCC[N+](C)(C)C USFMMZYROHDWPJ-UHFFFAOYSA-N 0.000 description 1
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 229940082894 vitis vinifera seed extract Drugs 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】
【発明の属する技術分野】
本発明は、優れた禁煙効果を有する、ニコチンまたはニコチンの塩を含有してなる軟膏剤に関する。
【0002】
【従来の技術】
従来、喫煙をやめたいと希望する人に対して、ニコチン渇望を削減するという目的で、ニコチンを含有する組成物を投与する禁煙療法が知られている。かかる組成物としては、例えば、特許文献1,2に記載の咀嚼可能組成物、特許文献3に記載の高粘度ニコチン点鼻組成物、特許文献4に記載のニコチン含有唾液可溶性軟膏、特許文献5に記載の鼻腔スプレイ投与に適した低粘度ニコチン含有組成物、特許文献6,7に記載の吸入エアロゾル、特許文献8,9に記載の液状エアロゾル製剤、特許文献10に記載のニコチン薬用ドロップなどが挙げられる。
しかしながら、これらのニコチン製剤は、実際に喫煙した場合に比して、体内へのニコチンの吸収速度が遅いため、十分な禁煙効果を得ることができない場合があった。
【0003】
この問題を解決すべく、特許文献11には、約25℃ないし約45℃、好ましくは約33℃ないし約45℃の融点範囲を有するニコチンのデリバリー用ニコチン含有医薬用組成物が提案されている。この医薬用組成物は、例えば、ニコチン含有錠剤を頬の粘膜と歯茎の間に押し込んで、頬の内側からニコチンを急速粘膜吸収させることにより、あるいはニコチン含有パッチ(シート状物)として皮膚に貼り付けてニコチンを経皮吸収させて、実際に喫煙した場合と同程度のニコチンの吸収速度を達成することを目的としている。
【0004】
しかしながら、この方法においては、禁煙治療の対象となる人がニコチン含有錠剤を噛みすぎると、ニコチンが溶出して、のどの痛みや胃痛を引き起こす場合があった。また、皮膚にパッチを貼り付ける場合には、皮膚がかぶれる場合があり、問題となっていた。
したがって、より簡便で安全に使用でき、かつ皮膚のかぶれなどを引き起こすことがない、優れた禁煙効果を得ることができるニコチン含有製剤の開発が求められていた。
【0005】
【特許文献1】
USP.3,845,217号公報
【特許文献2】
WO88/03803号公報
【特許文献3】
USP.4,579,858号公報
【特許文献4】
USP.5,525,351号公報
【特許文献5】
USP.5,656,255号公報
【特許文献6】
USP.4,920,989号公報
【特許文献7】
USP.4,953,572号公報
【特許文献8】
BP.1,528,391号公報
【特許文献9】
BP.2,030,862号公報
【特許文献10】
英国特許出願 GB.2230439A
【特許文献11】
特表2002−530335号公報
【0006】
【発明が解決しようとする課題】
本発明は、上記した従来技術に鑑みてなされたものであり、簡便かつ安全な方法により、優れた禁煙効果を得ることができるニコチン含有軟膏剤を提供することを課題とする。
【0007】
【課題を解決するための手段】
本発明者は、上記課題を解決すべく鋭意検討した結果、ニコチンまたはニコチンの塩および軟膏基材を含有してなるニコチン含有軟膏剤を調製した。そして、この軟膏剤を人間の皮膚、特に皮膚の薄い部分に塗布する(塗り込む)と、極めて短時間にニコチンが体内吸収され、優れた禁煙効果を得ることができることを見出し、本発明を完成するに到った。
【0008】
かくして本発明によれば、ニコチンまたはニコチンの塩および軟膏基材を含有することを特徴とするニコチン含有軟膏剤が提供される。
本発明の軟膏剤においては、前記軟膏基材が、少なくとも水、湿潤剤および増粘剤を含有するものであるのが好ましい。
また、本発明の軟膏剤は、ニコチンまたはニコチンの塩の含有量が、軟膏剤全体に対して、1〜5重量%であるのがより好ましい。
【0009】
【発明の実施の形態】
以下、本発明のニコチン含有軟膏剤を詳細に説明する。
本発明のニコチン含有軟膏剤は、ニコチンまたはニコチンの塩、および軟膏基材を含有してなることを特徴とする。
本発明の軟膏剤は、いわゆるニコチン中毒にあり、禁煙を希望する人の体内にニコチンまたはニコチンの塩を速やかに吸収させることにより、喫煙渇望を削減して、優れた禁煙効果を得ることができるものである。
【0010】
(1)ニコチンまたはニコチンの塩
本発明の軟膏剤は、必須成分としてニコチンまたはニコチンの塩を含有する。
ニコチンの塩としては特に制限されず、例えば、無機酸の塩、有機酸の塩、複塩、およびこれらの水和物などが挙げられる。ニコチンの塩の具体例としては、塩酸塩、硝酸塩、硫酸塩、リン酸塩などのニコチンの無機酸の塩;酢酸塩、乳酸塩、クエン酸塩、酒石酸塩、リンゴ酸塩、コハク酸塩などの脂肪族カルボン酸の塩;安息香酸塩、サリチル酸塩、フタル酸塩などの芳香族カルボン酸の塩;塩化亜鉛との複塩(double salt);などが挙げられる。これらの中でも、人間の皮膚に対する刺激が少なく、優れた禁煙効果を得る観点から、有機酸の塩が好ましく、芳香族カルボン酸の塩がより好ましく、サリチル酸塩の使用が特に好ましい。ニコチンまたはニコチンの塩は、市販されているものをそのまま用いることができる。また、ニコチンの塩は、ニコチンと対応する酸とを反応させて製造したものを用いることもできる。
【0011】
ニコチンまたはニコチンの塩の軟膏剤中の含有量は、特に制限されないが、安定なペーストを形成し、かつ、優れた禁煙効果を得る観点から、軟膏剤全体に対して、通常0.1〜10重量%、好ましくは1〜5重量%、より好ましくは1.5〜3重量%、特に好ましくは2〜3重量%である。
【0012】
(2)軟膏基材
本発明の軟膏剤は必須成分として、軟膏基材を含有する。軟膏基材は、活性成分(ニコチンまたはニコチンの塩)を溶解または練り込ませるための原料となるものである。
軟膏基材の成分は重要であり、皮膚の状態に適応したものを選択する必要がある。軟膏基材は、油脂性基材、乳剤性基材、水溶性基材などに分類できるが、軟膏剤を皮膚に塗布することにより、ニコチンまたはニコチンの塩を速やかに経皮吸収させる上では、皮膚浸透作用が優れる乳剤性基材または水溶性基材が好ましく、乳剤性基材がより好ましい。
【0013】
なかでも、本発明に用いる軟膏基材としては、少なくとも水、湿潤剤および増粘剤を含有するものであるのが特に好ましい。このような軟膏基材を用いることにより、皮膚に刺激がなく、伸びがよく、かつ、ニコチンまたはニコチンの塩が速やかに経皮吸収され、優れた禁煙効果を発揮する軟膏剤を得ることができる。
【0014】
湿潤剤は、水分の保持を促進する化合物であり、加湿剤とも呼ばれる。湿潤剤としては、例えば、エトキシジグリコール、ソルビトール、グリセリン、グリセレス(glycereth)5乳酸塩、グリセレス7三酢酸塩、グリセレス7ジイソナノエート、ヘキサントリオール、ヘキシレングリコール、プロピレングリコール、アルコキシル化グルコース、D−パンテノールおよびそれらの誘導体、ヒアルロン酸、グリセリンのプロピレンオキシド、加水分解コーンスターチ、加水分解コムギタンパク質/コムギオリゴ糖、加水分解トウモロコシタンパク質、加水分解コムギグルテン、加水分解酵母タンパク質、加水分解植物タンパク質、加水分解大豆タンパク質、加水分解米タンパク質、加水分解ジャガイモタンパク質などが挙げられる。これらの湿潤剤は1種単独で、あるいは2種以上を組み合わせて用いることができる。
【0015】
増粘剤は、水に溶解または分散して粘稠性を生じる高分子物質である。増粘剤としては、例えば、ヒドロキシエチルセルロース、メチルセルロース、ヒドロキシプロピルセルロース、カルボキシメチルセルロースなどのセルロース誘導体;いなごまめガム、グアーガム、ヒドロキシプロピルグアーガム、キサンタンガム、ポリアクリル酸またはその塩、ラノリン、ギルセロールポリ(メタ)アクリレートポリマー、ポリビニルピロリドン、ポリビニルアルコール、アクリルアミドとアンモニウムアクリレートとの架橋ポリマー、アクリルアミドと2−アクリルアミド−2−メチルプロパンスルホニックアシッドの架橋ポリマーおよびその一部または完全中和物、アクリルアミドとメタクリロイルオキシエチルトリメチルアンモニウムクロライドとの架橋ポリマー、アクリル酸より誘導されるホモポリマーまたはコポリマー、ポリウレタンラテックスなどが挙げられる。これらの増粘剤は1種単独で、あるいは2種以上を組み合わせて用いることができる。
【0016】
軟膏基材中の水の含有量は、軟膏剤全体に対し、5〜50重量%、好ましくは10〜40重量%、より好ましくは15〜30重量%である。
湿潤剤の含有量は、軟膏剤全体に対し、通常1〜30重量%、好ましくは10〜25重量%である。湿潤剤の含有量がこの範囲にあるときに、皮膚との親和性が高く、伸びの良い軟膏剤を得ることができる。
また、増粘剤の含有量は、軟膏剤全体に対し、通常0.1〜10重量%、好ましくは1〜5重量%である。
水、湿潤剤および増粘剤の含有量がこれらの範囲にあるときに、保湿性に優れ、皮膚との親和性が高く、伸びがよく、かつ、ニコチンまたはニコチンの塩の経皮吸収性に優れた軟膏剤を得ることができる。
【0017】
前記軟膏基材には、水、湿潤剤および増粘剤に加えて、所望により他の成分を含有せしめることができる。他の成分としては、通常の軟膏剤や化粧品に用いられるもの、例えば、安息香酸エステル、高級脂肪酸エステル、ポリシロキサン化合物、アルコール類、合成高分子、無機塩類、ビタミン類、植物由来物、香料類、アミノ酸類、油類、界面活性剤(乳化剤)などを使用できる。
【0018】
安息香酸エステルとしては、例えば、安息香酸の炭素数1〜20のアルキルエステルが挙げられる。なかでも、安息香酸の炭素数12〜15のアルキルエステルが好ましい。安息香酸の炭素数12〜15のアルキルエステルの具体例としては、安息香酸ドデシル、安息香酸トリデシル、安息香酸テトラデシル、安息香酸ペンタデシル、およびこれらの混合物などが挙げられる。
【0019】
高級脂肪酸エステルとしては、例えば、炭素数が12以上の長鎖脂肪酸のグリセロールやコレステロールのエステルが挙げられる。例えば、ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸などの飽和脂肪酸のエステル;オレイン酸、リノール酸、リノレン酸(α、γ異性体)などの不飽和脂肪酸のエステル;などが挙げられる。
【0020】
ポリシロキサン化合物は、主鎖にシロキサン結合(−Si−O−)を有する重合体である。例えば、ポリジメチルシロキサン、ポリメチルフェニルシロキサン、ポリジフェニルシロキサンなどが挙げられる。
【0021】
アルコール類としては、例えば、エタノール、フェノキシエタノール、デカノール、ウンデカノール、ドデカノール、トリデカノール、テトラデカノール、ペンタデカノール、ヘキサデカノール(セチルアルコール)、ヘプタデカノール、オクタデカノール、セテアリルアルコール(Cetearyl Alcohol)などが挙げられる。
【0022】
合成高分子としては、例えば、ポリアクリルアミド、ポリアミドなどが挙げられる。
無機塩類としては、例えば、ケイ酸マグネシウム、アルミノシリケート、ウォスラナイト、チタン酸カリウム、塩基性硫酸マグネシウム、セピオライト、ゾノトライト、酸化亜鉛、マイカなどが挙げられる。
ビタミン類としては、例えば、ビタミンA パルミテート、ビタミンE アセテート(トコフェリルアセテート)、ビタミンC パルミテートなどが挙げられる。
【0023】
植物由来物としては、通常の化粧品に用いることができるものが使用できる。例えば、アロエ・ベラ(または抽出液)、ブドウの実の抽出物(Vitis Vinifera seed extract)、コムギ胚芽油(Triticum Vulgare Germ Oil)、ウィートエキストラクト、アカブドウエキス、アセンヤクエキス、アボガドオイル、アルテアエキス、アルニカエキス、オウゴンエキス、オウレンエキス、オリザノール、カミツレエキス、クインスシードエキス、ヤグルマエキス、アシタバエキス、ニンジンエキスなどが挙げられる。
【0024】
香料類は、植物性香料、動物性香料、合成香料の種々のものが使用できる。例えば、ピネン、リネモール、アネトール、シネオール、青葉アルコール、ゲラニオール、シトロネロール、テルピネオール、フェネチルアルコール、メントール、リナロール、オイゲノール、シンナミルアルデヒド、シトラール、シトロネラール、シンナミルアルデヒド、リラール、イオノン、ジャスモン、クマリンなどが挙げられる。
【0025】
アミノ酸類としては、ヒドロキシメチルグリシン ナトリウム塩、グリシン、メチオニン、イソロイシン、アルギニンなどが挙げられる。
油類としては、カーネル油(Kernel oil)、アーモンドオイル、オリーブオイル、椿油、ヒマシ油、ココナッツ油、マカデミアンナッツ油、ミンク油、ヤシ油、ラノリン、ゴマ油、スクワランオイルなどが挙げられる。
【0026】
界面活性剤(乳化剤)としては、その性質により、アニオン界面活性剤、カチオン界面活性剤、ノニオン界面活性剤、両性界面活性剤の種々のものが使用できる。例えば、セテアリルグルコシド(Cetearyl Glucoside)、EDTA四ナトリウム塩、エタノールアミン、ジエタノールアミン、ジイソプロパノールアミン、トリエタノールアミン、ポリエチレングリコール、ポリオキシエチレン脂肪酸エステル、ラウリル硫酸、ラウリル硫酸ナトリウムなどが挙げられる。
これら他の成分は、それぞれ1種単独で、あるいは2種以上を組み合わせて用いることができる。
【0027】
これらの他の成分の合計含有量は、軟膏剤全体に対して、1重量%以下、好ましくは0.5重量%以下、より好ましくは0.4重量%以下である。また、個々の他の成分の含有量は、それぞれ0.1重量%以下であるのが好ましい。
【0028】
(3)軟膏剤の調製方法
本発明の軟膏剤は、ニコチンまたはニコチンの塩の所定量と、軟膏基材の所定量とを混合して、十分に混練することにより調製することができる。混練方法は特に制約されず、公知の混練機を用いて行うことができる。また、少量の場合には、例えば、ニコチンまたはニコチンの塩の所定量と軟膏基材の所定量を、乳鉢またはミキサー内に入れ、全体が均一になるまで十分に練り合わせればよい。
【0029】
以上のようにして得られる軟膏剤は、適度な稠度(consistency)を有する略均一(homogeneous)な半固形状(semi solid)に製剤化された、皮膚に塗布する外用剤である。
【0030】
本発明の軟膏剤は、禁煙を希望する人間の皮膚、特に上腕部の内側、顎の下、下瞼部分などの皮の薄い部分に所定量を塗布する(塗り込む)ことにより、速やかにニコチンまたはニコチンの塩が体内に吸収される。いわゆるニコチン中毒と呼ばれる症状の人は、血中のニコチン濃度が低下すると、ニコチンを渇望する(すなわち、喫煙を欲求する)。本発明の軟膏剤を皮膚に塗布すると、血中濃度が喫煙したときと同程度にまで高められるために、喫煙渇望を削減できると考えられる。
【0031】
本発明の軟膏剤を使用する時期は特に制約されず、喫煙を欲求するときに所定量を皮膚に塗布すればよい。例えば、就寝前に喫煙する習慣のある人の場合には就寝前、起床直後に喫煙する習慣のある人の場合には起床直後、食後に喫煙する習慣がある人の場合には食後である。本発明の軟膏剤の塗布量は特に制限されず、禁煙を希望する人のニコチン依存度にもよるが、通常0.1g〜2g程度である。
【0032】
本発明の軟膏剤を塗布後、喫煙願望がなくなる状態(禁煙効果)が認められるまでの時間は、通常、塗布後30分以内、好適には塗布後20分以内である。また、効果の持続時間は個人差があるが、通常3時間〜12時間である。
【0033】
本発明の軟膏剤を使用することにより、軟膏剤を使用後、次の喫煙渇望が現れるまでの時間が次第に長くなる傾向が一般的に認められる。その結果、喫煙量(喫煙するタバコの本数)を約半分以下に低減させることができる。
喫煙する習慣を完全に絶ち、禁煙を完全に達成するためには、ニコチン依存症も治癒しなければならない。そのためには、本発明の軟膏剤を使用することによって、先ず、喫煙する習慣をやめさせ、次いで、本発明の軟膏剤の使用量(塗布量、使用回数など)を徐々に減らしていけばよい。
【0034】
【実施例】
以下、実施例により、本発明をさらに詳細に説明する。本発明は以下の実施例に限定されず、ニコチンの塩の種類、軟膏基材の組成、組成割合などを、本発明の主旨を逸脱しない範囲で自由に変更することができる。
【0035】
実施例 ニコチン含有軟膏剤の製造
水22重量部、軟膏基材75.6重量部およびニコチンのサリチル酸塩2.4重量部を乳鉢内で混合し、十分に練り合わせて、淡黄色のニコチン含有軟膏剤を得た。
軟膏基材としては、以下の成分からなるものを用いた。
グリセリン18重量%、炭素数12〜15のアルキルベンゾエート15重量%、ステアリン酸グリセリル12重量%,ジメチルポリシロキサン8.75重量%、セテアリルアルコール4.5重量%、セテアリルグルコシド3.5重量%、ポリアクリルアミド、ヘキサデカノール2.5重量%、マグネシウムケイ酸塩1.5重量%、ギンサンガム(高分子多糖)1.5重量%、アロエエキス(アロエ・バルバデンス)1重量%、ビタミンEの酢酸エステル(酢酸トコフェロール)0.5重量%、プラナス・アミガダルス・アマラ(香料ハーブの1種)0.25重量%、カーネル油0.2重量%、エトキシジグリコール1.25重量%、乳化剤(商品名:Krisgel 100、Professional Compounding Centers of America社製)0.3重量%
【0036】
禁煙効果試験
喫煙習慣のある20才から40才までの女性30人、および40才から60才までの男性5人を被試験者とした。実施例で得たニコチン含有軟膏剤の0.5gを、喫煙欲求がある被試験者の皮膚の上腕部内側に塗布した(塗り込んだ)。軟膏剤を塗布後15分〜20分以内に、すべての被試験者には喫煙渇望がなくなった。また、外見上も、喫煙習慣のある人に顕著に認められる、喫煙渇望時のイライラなどがなくなっていた。
【0037】
その後、喫煙欲求がある度に、各被試験者の皮膚にニコチン含有軟膏剤を塗布した。軟膏剤の塗布は、被試験者の上腕部の内側の皮膚部分と顎の下の皮膚部分とに交互に行った。
ニコチン含有軟膏剤を塗布してから、次の喫煙欲求までの間隔は、平均で3〜4時間であった。また、この間隔は実施例の軟膏剤の塗布を繰り返すたびに長くなる傾向にあった。
【0038】
喫煙欲求がある度にニコチン含有軟膏剤を塗布することを1ヶ月間継続した結果、被試験者の全員について、タバコの喫煙本数が半分以下に減少した。また、この効果の男女間差はなく、軟膏剤を塗布することにより、皮膚にかぶれなどの異常が生じた人もいなかった。
【0039】
【発明の効果】
本発明の軟膏剤によれば、皮膚に塗布するという極めて簡便、かつ安全な方法により、優れた禁煙効果を得ることができる。
また、本発明の軟膏剤は、皮膚との親和性に優れ、伸びがよく、ニコチンまたはニコチンの塩が速やかに経皮吸収される。従って、本発明の軟膏剤を人間の皮膚、特に皮膚の薄い部分に塗布することにより、極めて短時間にニコチンが体内吸収され、優れた禁煙効果を得ることができる。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to an ointment containing nicotine or a nicotine salt, which has an excellent smoking cessation effect.
[0002]
[Prior art]
BACKGROUND ART Conventionally, smoking cessation therapy in which a nicotine-containing composition is administered to a person who desires to quit smoking for the purpose of reducing nicotine craving is known. Examples of such a composition include a chewable composition described in Patent Documents 1 and 2, a high-viscosity nicotine nasal composition described in Patent Document 3, a nicotine-containing saliva-soluble ointment described in Patent Document 4, and Patent Document 5 Low-viscosity nicotine-containing composition suitable for nasal spray administration described in Patent Documents 6 and 7, inhalation aerosols described in Patent Documents 6 and 7, liquid aerosol preparations described in Patent Documents 8 and 9, nicotine drug drops described in Patent Document 10 and the like. No.
However, these nicotine preparations may not be able to obtain a sufficient smoking cessation effect because the absorption rate of nicotine into the body is lower than when actually smoking.
[0003]
In order to solve this problem, Patent Document 11 proposes a nicotine-containing pharmaceutical composition for delivering nicotine having a melting point range of about 25 ° C to about 45 ° C, preferably about 33 ° C to about 45 ° C. . This pharmaceutical composition can be applied to the skin by, for example, pressing a nicotine-containing tablet between the mucous membrane of the cheek and the gums to rapidly absorb nicotine from the inside of the cheek, or as a nicotine-containing patch (sheet-like material). It is intended to allow nicotine to be absorbed percutaneously to achieve a nicotine absorption rate comparable to that of actual smoking.
[0004]
However, in this method, if the person to be treated for smoking cessation chews too much on the nicotine-containing tablet, nicotine may elute and cause sore throat or stomach pain. Also, when a patch is applied to the skin, the skin may be rash, which has been a problem.
Therefore, the development of a nicotine-containing preparation that can be used more easily and safely and that does not cause skin irritation or the like and that can obtain an excellent smoking cessation effect has been demanded.
[0005]
[Patent Document 1]
USP. 3,845,217 [Patent Document 2]
WO88 / 03803 [Patent Document 3]
USP. 4,579,858 [Patent Document 4]
USP. No. 5,525,351 [Patent Document 5]
USP. No. 5,656,255 [Patent Document 6]
USP. 4,920,989 [Patent Document 7]
USP. 4,953,572 [Patent Document 8]
BP. No. 1,528,391 [Patent Document 9]
BP. Japanese Patent No. 2,030,862 [Patent Document 10]
UK patent application GB. 2230439A
[Patent Document 11]
JP 2002-530335 A
[Problems to be solved by the invention]
The present invention has been made in view of the above-mentioned prior art, and has as its object to provide a nicotine-containing ointment capable of obtaining an excellent smoking cessation effect by a simple and safe method.
[0007]
[Means for Solving the Problems]
As a result of intensive studies to solve the above-mentioned problems, the present inventors have prepared a nicotine-containing ointment containing nicotine or a nicotine salt and an ointment base. Then, when this ointment is applied to human skin, especially on a thin part of the skin, the nicotine is absorbed into the body in a very short time, and it has been found that an excellent smoking cessation effect can be obtained, and the present invention has been completed. I came to.
[0008]
Thus, according to the present invention, there is provided a nicotine-containing ointment comprising nicotine or a salt of nicotine and an ointment base.
In the ointment of the present invention, the ointment base preferably contains at least water, a wetting agent and a thickener.
In the ointment of the present invention, the content of nicotine or a nicotine salt is more preferably 1 to 5% by weight based on the whole ointment.
[0009]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, the nicotine-containing ointment of the present invention will be described in detail.
The nicotine-containing ointment of the present invention is characterized by containing nicotine or a nicotine salt, and an ointment base.
The ointment of the present invention is in so-called nicotine poisoning, and by rapidly absorbing nicotine or a salt of nicotine into the body of a person who wants to quit smoking, it is possible to reduce smoking craving and obtain an excellent smoking cessation effect. Things.
[0010]
(1) Nicotine or nicotine salt The ointment of the present invention contains nicotine or a nicotine salt as an essential component.
The salt of nicotine is not particularly limited, and examples thereof include salts of inorganic acids, salts of organic acids, double salts, and hydrates thereof. Specific examples of nicotine salts include salts of inorganic acids of nicotine such as hydrochloride, nitrate, sulfate, phosphate; acetate, lactate, citrate, tartrate, malate, succinate, etc. Salts of aromatic carboxylic acids such as benzoate, salicylate, and phthalate; double salts with zinc chloride; and the like. Among these, salts of organic acids are preferred, salts of aromatic carboxylic acids are more preferred, and salicylates are particularly preferred from the viewpoint of less irritation to human skin and excellent smoking cessation effects. As nicotine or nicotine salts, commercially available ones can be used as they are. As the nicotine salt, those produced by reacting nicotine with a corresponding acid can also be used.
[0011]
The content of nicotine or a salt of nicotine in the ointment is not particularly limited, but from the viewpoint of forming a stable paste and obtaining an excellent smoking cessation effect, the content is usually 0.1 to 10 with respect to the whole ointment. % By weight, preferably 1 to 5% by weight, more preferably 1.5 to 3% by weight, particularly preferably 2 to 3% by weight.
[0012]
(2) Ointment base The ointment of the present invention contains an ointment base as an essential component. The ointment base is a raw material for dissolving or kneading the active ingredient (nicotine or a nicotine salt).
The components of the ointment base are important, and it is necessary to select one suitable for the condition of the skin. Ointment bases, oily bases, emulsion bases, water-soluble bases, etc., can be classified, but by applying the ointment to the skin, in order to quickly transdermally absorb nicotine or nicotine salts, Emulsion bases or water-soluble bases having excellent skin penetration are preferred, and emulsion bases are more preferred.
[0013]
Among these, the ointment base used in the present invention particularly preferably contains at least water, a wetting agent and a thickener. By using such an ointment base material, there is no irritation to the skin, good elongation, and nicotine or a nicotine salt is rapidly transdermally absorbed, and an ointment exhibiting an excellent smoking cessation effect can be obtained. .
[0014]
Wetting agents are compounds that promote retention of moisture and are also called humidifiers. Examples of the wetting agent include ethoxydiglycol, sorbitol, glycerin, glycereth 5 lactate, glyceres 7-triacetate, glyceres 7 diisonanoate, hexanetriol, hexylene glycol, propylene glycol, alkoxylated glucose, and D-pan. Tenol and derivatives thereof, hyaluronic acid, propylene oxide of glycerin, hydrolyzed corn starch, hydrolyzed wheat protein / wheat oligosaccharide, hydrolyzed corn protein, hydrolyzed wheat gluten, hydrolyzed yeast protein, hydrolyzed plant protein, hydrolyzed soy protein , Hydrolyzed rice protein, hydrolyzed potato protein and the like. These wetting agents can be used alone or in combination of two or more.
[0015]
Thickeners are polymeric substances that become viscous when dissolved or dispersed in water. Examples of the thickener include cellulose derivatives such as hydroxyethylcellulose, methylcellulose, hydroxypropylcellulose and carboxymethylcellulose; locust bean gum, guar gum, hydroxypropyl guar gum, xanthan gum, polyacrylic acid or a salt thereof, lanolin, gilcerol poly (meth) acrylate Polymer, polyvinylpyrrolidone, polyvinyl alcohol, crosslinked polymer of acrylamide and ammonium acrylate, crosslinked polymer of acrylamide and 2-acrylamido-2-methylpropanesulfonic acid and partially or completely neutralized product thereof, acrylamide and methacryloyloxyethyltrimethylammonium Crosslinked polymer with chloride, homopolymer or copolymer derived from acrylic acid Rimmer, such as a polyurethane latex, and the like. These thickeners can be used alone or in combination of two or more.
[0016]
The content of water in the ointment base is 5 to 50% by weight, preferably 10 to 40% by weight, more preferably 15 to 30% by weight, based on the whole ointment.
The content of the wetting agent is usually 1 to 30% by weight, preferably 10 to 25% by weight, based on the whole ointment. When the content of the wetting agent is within this range, an ointment having high affinity with the skin and good elongation can be obtained.
The content of the thickener is usually 0.1 to 10% by weight, preferably 1 to 5% by weight, based on the whole ointment.
When the content of water, humectant and thickener is in these ranges, it has excellent moisturizing properties, high affinity with the skin, good elongation, and percutaneous absorption of nicotine or nicotine salt. An excellent ointment can be obtained.
[0017]
The ointment base may contain other components as desired in addition to water, a wetting agent and a thickener. As other components, those used in ordinary ointments and cosmetics, for example, benzoic acid esters, higher fatty acid esters, polysiloxane compounds, alcohols, synthetic polymers, inorganic salts, vitamins, plant-derived substances, fragrances , Amino acids, oils, surfactants (emulsifiers) and the like.
[0018]
Examples of the benzoic acid ester include an alkyl ester of benzoic acid having 1 to 20 carbon atoms. Among them, alkyl esters of benzoic acid having 12 to 15 carbon atoms are preferred. Specific examples of the alkyl ester of benzoic acid having 12 to 15 carbon atoms include dodecyl benzoate, tridecyl benzoate, tetradecyl benzoate, pentadecyl benzoate, and mixtures thereof.
[0019]
Examples of higher fatty acid esters include glycerol and cholesterol esters of long-chain fatty acids having 12 or more carbon atoms. Examples include esters of saturated fatty acids such as lauric acid, myristic acid, palmitic acid, and stearic acid; esters of unsaturated fatty acids such as oleic acid, linoleic acid, and linolenic acid (α and γ isomers).
[0020]
The polysiloxane compound is a polymer having a siloxane bond (—Si—O—) in the main chain. For example, polydimethylsiloxane, polymethylphenylsiloxane, polydiphenylsiloxane, and the like can be given.
[0021]
As alcohols, for example, ethanol, phenoxyethanol, decanol, undecanol, dodecanol, tridecanol, tetradecanol, pentadecanol, hexadecanol (cetyl alcohol), heptadecanol, octadecanol, cetearyl alcohol (Cetearyl Alcohol) And the like.
[0022]
Examples of the synthetic polymer include polyacrylamide and polyamide.
Examples of the inorganic salts include magnesium silicate, aluminosilicate, wuslanite, potassium titanate, basic magnesium sulfate, sepiolite, zonotlite, zinc oxide, mica, and the like.
Examples of the vitamins include vitamin A palmitate, vitamin E acetate (tocopheryl acetate), vitamin C palmitate, and the like.
[0023]
As the plant-derived material, those that can be used for ordinary cosmetics can be used. For example, aloe vera (or extract), grape berry extract (Vitis Vinifera seed extract), wheat germ oil (Triticum Vulgare Germ Oil), wheat extract, red grape extract, asenyaku extract, avocado oil, altea Extract, arnica extract, gougon extract, spinach extract, oryzanol, chamomile extract, quince seed extract, cornflower extract, ashitaba extract, carrot extract and the like.
[0024]
Various flavors such as vegetable flavors, animal flavors, and synthetic flavors can be used as the flavors. For example, pinene, linenemol, anethole, cineole, green leaf alcohol, geraniol, citronellol, terpineol, phenethyl alcohol, menthol, linalool, eugenol, cinnamylaldehyde, citral, citronellal, cinnamylaldehyde, liral, ionon, jasmon, coumarin and the like. Can be
[0025]
Amino acids include hydroxymethylglycine sodium salt, glycine, methionine, isoleucine, arginine and the like.
Examples of oils include kernel oil, almond oil, olive oil, camellia oil, castor oil, coconut oil, macadamian nut oil, mink oil, coconut oil, lanolin, sesame oil, squalane oil, and the like.
[0026]
As the surfactant (emulsifier), various types of anionic surfactant, cationic surfactant, nonionic surfactant, and amphoteric surfactant can be used depending on their properties. Examples include cetearyl glucoside, tetrasodium EDTA, ethanolamine, diethanolamine, diisopropanolamine, triethanolamine, polyethylene glycol, polyoxyethylene fatty acid ester, lauryl sulfate, sodium lauryl sulfate, and the like.
These other components can be used alone or in combination of two or more.
[0027]
The total content of these other components is 1% by weight or less, preferably 0.5% by weight or less, more preferably 0.4% by weight or less based on the whole ointment. The content of each of the other components is preferably 0.1% by weight or less.
[0028]
(3) Preparation method of ointment The ointment of the present invention can be prepared by mixing a predetermined amount of nicotine or a nicotine salt with a predetermined amount of an ointment base, and kneading the mixture sufficiently. The kneading method is not particularly limited, and can be performed using a known kneading machine. In the case of a small amount, for example, a predetermined amount of nicotine or a salt of nicotine and a predetermined amount of an ointment base may be put in a mortar or a mixer and kneaded sufficiently until the whole becomes uniform.
[0029]
The ointment obtained as described above is an external preparation to be applied to the skin, which is formulated into a homogenous semi-solid (semi solid) having an appropriate consistency.
[0030]
The ointment of the present invention is quickly applied to nicotine by applying (applying) a predetermined amount to the skin of a human who wants to quit smoking, particularly to a thin part of the skin such as the inside of the upper arm, under the chin, and the lower eyelid. Or nicotine salts are absorbed into the body. A person with a condition called so-called nicotine addiction craves nicotine (i.e., desires to smoke) when the level of nicotine in the blood drops. It is considered that when the ointment of the present invention is applied to the skin, the blood concentration is increased to the same level as when smoking, and thus the craving for smoking can be reduced.
[0031]
The timing of using the ointment of the present invention is not particularly limited, and a predetermined amount may be applied to the skin when smoking is desired. For example, in the case of a person who has a habit of smoking before going to bed, it is before bedtime, in the case of a person who has a habit of smoking immediately after getting up, immediately after getting up, and in the case of a person who has a habit of smoking after eating, after eating. The amount of the ointment of the present invention to be applied is not particularly limited, and is usually about 0.1 g to 2 g, although it depends on the nicotine dependence of the person who wants to quit smoking.
[0032]
The time after the application of the ointment of the present invention until the state where the desire to smoke disappears (the smoking cessation effect) is recognized is usually within 30 minutes after application, and preferably within 20 minutes after application. The duration of the effect varies from individual to individual, but is usually from 3 hours to 12 hours.
[0033]
By using the ointment of the present invention, it is generally recognized that after using the ointment, the time until the next craving for smoking appears gradually becomes longer. As a result, the amount of smoking (the number of smoking cigarettes) can be reduced to about half or less.
Nicotine addiction must also be cured in order to completely abstain from smoking and achieve complete cessation. For that purpose, by using the ointment of the present invention, first, the smoking habit is stopped, and then the amount of the ointment of the present invention (the amount of application, the number of times of use, etc.) may be gradually reduced. .
[0034]
【Example】
Hereinafter, the present invention will be described in more detail with reference to examples. The present invention is not limited to the following examples, and the type of nicotine salt, the composition of the ointment base, the composition ratio, and the like can be freely changed without departing from the gist of the present invention.
[0035]
Example Production of nicotine-containing ointment 22 parts by weight of water, 75.6 parts by weight of an ointment base, and 2.4 parts by weight of nicotine salicylate were mixed in a mortar, kneaded well and mixed to give a pale yellow color. A nicotine-containing ointment was obtained.
As the ointment base, one composed of the following components was used.
Glycerin 18% by weight, C15-C15 alkyl benzoate 15% by weight, glyceryl stearate 12% by weight, dimethylpolysiloxane 8.75% by weight, cetearyl alcohol 4.5% by weight, cetearyl glucoside 3.5% by weight , Polyacrylamide, 2.5% by weight of hexadecanol, 1.5% by weight of magnesium silicate, 1.5% by weight of ginsan gum (high molecular weight polysaccharide), 1% by weight of aloe extract (Aloe barbadens), acetic acid of vitamin E 0.5% by weight of ester (tocopherol acetate), 0.25% by weight of Planas amigadalus amara (one of flavor herbs), 0.2% by weight of kernel oil, 1.25% by weight of ethoxydiglycol, emulsifier (trade name) : Krisgel 100, Professional Compounding Center of America, Inc.) 0.3 wt%
[0036]
Smoking cessation effect test Thirty women aged 20 to 40 and five men aged 40 to 60 who had a smoking habit were set as subjects. 0.5 g of the nicotine-containing ointment obtained in the example was applied (applied) to the inside of the upper arm of the skin of the subject who had a desire to smoke. Within 15-20 minutes after application of the ointment, all subjects had no craving for smoking. Also, apparently, the frustration of smoking cravings, which are remarkably observed in people with smoking habits, has disappeared.
[0037]
Thereafter, whenever there was a desire to smoke, a nicotine-containing ointment was applied to the skin of each subject. The ointment was applied alternately to the skin portion inside the upper arm of the subject and the skin portion under the chin.
The average interval between the application of the nicotine-containing ointment and the next desire to smoke was 3 to 4 hours. Also, this interval tended to be longer each time the application of the ointment of the example was repeated.
[0038]
As a result of continuing to apply the nicotine-containing ointment every time there was a desire for smoking, the number of cigarettes smoked decreased to less than half for all the test subjects. In addition, there was no difference between men and women in this effect, and there was no person who had an abnormality such as rash on the skin by applying the ointment.
[0039]
【The invention's effect】
According to the ointment of the present invention, an excellent smoking cessation effect can be obtained by a very simple and safe method of applying to the skin.
Further, the ointment of the present invention has excellent affinity with the skin, has good elongation, and allows nicotine or a nicotine salt to be rapidly transdermally absorbed. Therefore, by applying the ointment of the present invention to human skin, particularly to a thin part of the skin, nicotine is absorbed into the body in a very short time, and an excellent smoking cessation effect can be obtained.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002315622A JP2004149447A (en) | 2002-10-30 | 2002-10-30 | Nicotine-containing ointment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002315622A JP2004149447A (en) | 2002-10-30 | 2002-10-30 | Nicotine-containing ointment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004149447A true JP2004149447A (en) | 2004-05-27 |
Family
ID=32459565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002315622A Pending JP2004149447A (en) | 2002-10-30 | 2002-10-30 | Nicotine-containing ointment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2004149447A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008534483A (en) * | 2005-03-24 | 2008-08-28 | トランスフェイズ・リミテッド | Transdermal topical composition and use thereof |
| JP2016523979A (en) * | 2013-07-11 | 2016-08-12 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Nicotine salt with meta-salicylic acid |
| JP2016539636A (en) * | 2013-07-26 | 2016-12-22 | ディーエスエム アイピー アセッツ ビー.ブイ. | Improved powder formulations of organic acids or esters having aromatic ring systems |
| US11642473B2 (en) | 2007-03-09 | 2023-05-09 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| US12214119B2 (en) | 2018-02-02 | 2025-02-04 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
-
2002
- 2002-10-30 JP JP2002315622A patent/JP2004149447A/en active Pending
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008534483A (en) * | 2005-03-24 | 2008-08-28 | トランスフェイズ・リミテッド | Transdermal topical composition and use thereof |
| US12138383B2 (en) | 2007-03-09 | 2024-11-12 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| US11642473B2 (en) | 2007-03-09 | 2023-05-09 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| EP3019154A4 (en) * | 2013-07-11 | 2017-01-04 | Alexza Pharmaceuticals, Inc. | Nicotine salt with m eta-salicylic acid |
| US9724341B2 (en) | 2013-07-11 | 2017-08-08 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid |
| CN107049996A (en) * | 2013-07-11 | 2017-08-18 | 艾利斯达医药品公司 | With a nicotine salt for salicylic acid formation |
| US10166224B2 (en) | 2013-07-11 | 2019-01-01 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid and applications therein |
| JP2019006801A (en) * | 2013-07-11 | 2019-01-17 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Nicotine salt with meta-salicylic acid |
| US11458130B2 (en) | 2013-07-11 | 2022-10-04 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid and applications therein |
| JP2016523979A (en) * | 2013-07-11 | 2016-08-12 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Nicotine salt with meta-salicylic acid |
| JP2016539636A (en) * | 2013-07-26 | 2016-12-22 | ディーエスエム アイピー アセッツ ビー.ブイ. | Improved powder formulations of organic acids or esters having aromatic ring systems |
| US12214119B2 (en) | 2018-02-02 | 2025-02-04 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
| US12214118B2 (en) | 2018-02-02 | 2025-02-04 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7682623B2 (en) | Pharmaceutical composition for topical application | |
| US8512718B2 (en) | Pharmaceutical composition for topical application | |
| JP4697497B2 (en) | Wetting formulation | |
| JP2004535361A (en) | Bioadhesive sustained release closed cell foam film | |
| CN109152702A (en) | Composition for topical application of compound | |
| JP2001503069A (en) | Non-inflammatory cosmetic and pharmaceutical compositions | |
| CA2685321A1 (en) | Solubilized delivery system for topical anesthetics | |
| JP3665360B2 (en) | Active oxygen scavenger and composition containing the same | |
| US20110236503A1 (en) | Topical Skincare Composition | |
| JP2011088930A (en) | Carbon dioxide percutaneous and transmucosal absorption composition | |
| JP5643872B2 (en) | Carbon dioxide transdermal / mucosal absorption composition | |
| JP2002212107A (en) | Topical composition | |
| JP2004149447A (en) | Nicotine-containing ointment | |
| CN117883380B (en) | A transdermal emulsion for treating dry eye | |
| JP5164438B2 (en) | Carbon dioxide transdermal / mucosal absorption composition | |
| JP5699184B2 (en) | Carbon dioxide transdermal / mucosal absorption composition | |
| US11191795B2 (en) | Herbal compositions and methods for treating herpes | |
| JP3689137B2 (en) | Topical agent for treatment of allergic skin disease | |
| US10722586B2 (en) | Filmogenic compositions for topical anaesthetic bioadhesives—tabs, for controlled release of active principles and topical anaesthetic bioadhesives | |
| JPWO2005000316A1 (en) | External preparation for improving sexual function | |
| JP7706218B2 (en) | Sebum secretion promoter | |
| KR100347883B1 (en) | New pharmaceutical composition of gel preparation containing local anaesthetic agents | |
| CN113713000B (en) | Main medicine component composition for treating sore carbuncle, burn, scald and acne, sustained and controlled release pharmaceutical preparation, and preparation method and application thereof | |
| JP5993336B2 (en) | Carbon dioxide transdermal / mucosal absorption composition | |
| JP7678657B2 (en) | Sebum secretion promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060823 |
|
| A02 | Decision of refusal |
Effective date: 20061220 Free format text: JAPANESE INTERMEDIATE CODE: A02 |